PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4.

PAMD-Ch17 is a polymer composed of the CXCR4 inhibitor AMD3100/Plerixafor with a cholesterol modification. In previous work, we showed that PAMD-Ch17, but not AMD3100, induces cell death and differentiation in mouse acute myeloid leukemia cells. To investigate the mechanism of PAMD-Ch17's novel antileukemic effects, we tested PAMD-Ch17 against a panel of human leukemia cell lines and found that PAMD-Ch17 is effective against a variety of acute leukemias, with T-cell acute lymphoblastic leukemia (T-ALL) cell lines being highly sensitive. Surprisingly, CXCR4 knockout T-ALL cells were equally sensitive to PAMD-Ch17. Using a fluorescently tagged PAMD-Ch17, we found that the drug colocalized to mitochondria. We also found that PAMD-Ch17 induced changes in the expression of genes related to mitochondrial function, increased levels of mitochondrial superoxide, and decreased mitochondrial membrane potential. Using Seahorse assays, we found that PAMD-Ch17 decreased baseline oxygen consumption, ATP production, and proton leakage. In addition, we identified ATP synthase subunits as binding partners of PAMD-Ch17 and showed that the polymer, but not AMD3100, inhibited ATP synthase activity. In mouse primary T-ALL, but not healthy bone marrow cells, PAMD-Ch17 induced both mitochondrial superoxide and cell death. Using human bone marrow organoids, we found that PAMD-Ch17 induced mitochondrial superoxide and cell death in T-ALL cells from patients, but not in healthy stromal and hematopoietic cells. Collectively, our results indicate that PAMD-Ch17 has antileukemic effects against T-ALL cells but not healthy cells, likely mediated through a CXCR4-independent, mitochondrial-based mechanism. These findings support the further development of PAMDs as potential therapeutics for patients with T-ALL.